Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics

Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics PR Newswire MOUNTAIN VIEW, California, Aug. 13, 2012 - The company's commitment and planning have made its flagship product an indispensable diagnostic tool for CUP patients MOUNTAIN VIEW, California, Aug. 13, 2012 /PRNewswire/ -- Based on its recent analysis of the next-generation diagnostics market, Frost & Sullivan recognizes Rosetta Genomics with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. Rosetta Genomics successfully competes in a concentrated market and achieved significant product adoption, while bringing value to both patients and investors. A recent Frost & Sullivan analysis on the United States cancer biomarkers market confirmed the growing credibility of clinical microRNA biomarkers, as compared to other potential clinical biomarkers, such as circulating tumor cells. Rosetta Genomics was one of the first providers of microRNA-based diagnostics in 2007, and the platform is now clinically validated and featured in 37 peer- reviewed publications. Rosetta Genomics holds a leading patent position in the competitive microRNA diagnostics space. Building upon this foundation, it now has four microRNA-based diagnostic products on the market.